MD Bioproducts Releases Recombinant Human ST2 Protein for Use in a Variety of Research Applications

Share Article

MD Bioproducts Recombinant Human ST2 protein comprises a 310 amino acid fragment (19-328) corresponding to the soluble ST2 coding sequence and is expressed in E. coli with an amino-terminal hexahistidine tag.

MD Bioproducts, a division of MD Biosciences, Inc. announces the launch of a Recombinant Human ST2 protein expressed from E. coli. MD Bioproducts offers a full line of ST2 products for use in a variety of research applications:

Monoclonal Antibody to mouse T1/ST2 (clone DJ8)
Monoclonal Antibody to human ST2L (clone B4E6)
Recombinant Human ST2 Protein
Mouse T1/ST2 ELISA

The ST2 gene is a member of the IL-1 receptor family, encoding a transmembrane protein with a structure similar to IL-1R1. A soluble form of the protein (ST2) is produced from the same gene by alternative splicing and is reported to be expressed in several cell types including fibroblasts and mast cells. Soluble ST2 has been reported to act as a negative regulator of Th2 cytokine production and elavated levels have been reported in several disease states and conditions including asthma, sepsis, and myocardial infarction.

About MD Bioproducts
MD Bioproducts is a division of the privately-owned company MD Biosciences, Inc. offering products for use in the inflammations, neurology, endocrinology, and metabolic disorders research fields. Since beginning operations in the U.S., based out of St. Paul, Minnesota, MD Biosciences has experienced significant development and grown to a company of 60 employees.
http://www.mdbioproducts.com

About MD Biosciences
MD Biosciences provides pre-clinical contract research services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies' in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

AMY CLAUSEN
Visit website